Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mallinckrodt Finalizes Bankruptcy Filing And Opioid, Acthar Settlements

Executive Summary

The company will pay $1.6bn to settle opioid litigation and $260m to settle a Medicaid rebate dispute related to Acthar Gel under a restructuring support agreement.

You may also be interested in...



Did OxyContin Labeling Change Help Fuel Opioid Epidemic? Republicans Want More Data From FDA

Members of House Energy & Commerce Committee reiterate concerns that 2001 label revision may have been used to help promote higher dosage and longer-term prescriptions of OxyContin. J&J boosts opioid litigation settlement offer to $5bn.

Regeneron Leaders On Getting A Call From Trump And Building A Bioreactor Farm

Regeneron CEO Len Schleifer and President George Yancopoulos talked at the Stat Summit about launching their COVID-19 antibody cocktail and planning for the next pandemic.

Bill Gates On Vaccine Distribution Challenges, Overcoming Vaccine Hesitancy

The public health advocate and billionaire philanthropist raised issues about how a mass COVID-19 vaccination effort is being handled so far in the US, speaking at the Stat Summit.

Topics

Related Companies

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel